Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice.

Détails

ID Serval
serval:BIB_A6428C3D7E67
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice.
Périodique
Gene Therapy
Auteur⸱e⸱s
Hung C.F., Tsai Y.C., He L., Coukos G., Fodor I., Qin L., Levitsky H., Wu T.C.
ISSN
0969-7128 (Print)
ISSN-L
0969-7128
Statut éditorial
Publié
Date de publication
2007
Volume
14
Numéro
1
Pages
20-29
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.Publication Status: ppublish
Résumé
Vaccinia virus has been shown to efficiently infect tumor cells. Therefore, vaccinia virus represents a potentially safe and effective antitumor agent against ovarian cancer. Here, we assessed the ability of vaccinia virus to preferentially infect and control both human and murine ovarian tumors in vivo. We used the non-invasive luminescence imaging system to monitor the infection and suppression of ovarian tumors by vaccinia in live mice. Our data indicated that vaccinia was able to effectively infect and kill both human and murine ovarian tumors. Vaccinia virus administered to mice intraperitoneally was specifically targeted to the murine or human ovarian tumors and led to antitumor responses. These findings suggest that vaccinia virus is capable of selectively targeting and controlling ovarian tumors. Thus, intraperitoneal injection with vaccinia virus may provide a potentially effective strategy for treating advanced-stage ovarian cancers.
Mots-clé
Animals, Cell Line, Tumor, Female, Genetic Therapy/methods, Humans, Luciferases/genetics, Mice, Mice, Inbred C57BL, Mice, Nude, Neoplasm Transplantation, Oncolytic Virotherapy/methods, Ovarian Neoplasms/therapy, Ovarian Neoplasms/virology, Transfection/methods, Vaccinia/transmission, Vaccinia virus/genetics
Pubmed
Web of science
Open Access
Oui
Création de la notice
14/10/2014 12:42
Dernière modification de la notice
20/08/2019 16:11
Données d'usage